| [1] |
Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(10): 1985-1996.
|
| [2] |
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820.
|
| [3] |
Zhou X, Niu X, Mao Q, et al. Clinical significance of various classification standards of age groups in predicting survival of patients with glioblastoma[J]. Med Sci Monit, 2020, 26: e920627.
|
| [4] |
Karsy M, Yoon N, Boettcher L, et al. Surgical treatment of glioblastoma in the elderly: the impact of complications[J]. J Neurooncol, 2018, 138(1): 123-132.
|
| [5] |
Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article[J]. J Neurosurg, 2012, 117(6): 1032-1038.
|
| [6] |
Vuorinen V, Hinkka S, Färkkilä M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study[J]. Acta Neurochir (Wien), 2003, 145(1): 5-10.
|
| [7] |
Chaichana KL, Garzon-Muvdi T, Parker S, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients[J]. Ann Surg Oncol, 2011, 18(1): 239-245.
|
| [8] |
Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival[J]. J Neurooncol, 2011, 103(3): 611-618.
|
| [9] |
Almenawer SA, Badhiwala JH, Alhazzani W, et al. Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis[J]. Neuro Oncol, 2015, 17(6): 868-881.
|
| [10] |
Li T, Liu Y, Li J, et al. Do elderly patients (≥75 years old) with glioblastoma benefit from more radical surgeries in the era of temozolomide?[J]. Neurosurg Rev, 2021-07-09.
|
| [11] |
Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas[J]. Int J Radiat Oncol Biol Phys, 1979, 5(10): 1725-1731.
|
| [12] |
Iwamoto FM, Reiner AS, Panageas KS, et al. Patterns of care in elderly glioblastoma patients[J]. Ann Neurol, 2008, 64(6): 628-634.
|
| [13] |
Grau JJ, Verger E. Radiotherapy of the brain in elderly patients. Pro:[J]. Eur J Cancer, 2000, 36(4): 443-447.
|
| [14] |
Brandes AA, Rigon A, Monfardini S. Radiotherapy of the brain in elderly patients: Contra.[J]. Eur J Cancer, 2000, 36(4): 447-451; discussion 451-452.
|
| [15] |
Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly[J]. N Engl J Med, 2007, 356(15): 1527-1535.
|
| [16] |
Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial[J]. Lancet Oncol, 2012, 13(9): 916-926.
|
| [17] |
Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial[J]. J Clin Oncol, 2004, 22(9): 1583-1588.
|
| [18] |
Minniti G, Scaringi C, Lanzetta G, et al. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis[J]. Int J Radiat Oncol Biol Phys, 2015, 91(1): 109-115.
|
| [19] |
Cabrera AR, Kirkpatrick JP, Fiveash JB, et al. Radiation therapy for glioblastoma: executive summary of an American society for radiation oncology evidence-based clinical practice guideline[J]. Pract Radiat Oncol, 2016, 6(4): 217-225.
|
| [20] |
Zarnett OJ, Sahgal A, Gosio J, et al. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis[J]. JAMA Neurol, 2015, 72(5): 589-596.
|
| [21] |
Lütgendorf-Caucig C, Freyschlag C, Masel EK, et al. Guiding treatment choices for elderly patients with glioblastoma by a comprehensive geriatric assessment[J]. Curr Oncol Rep, 2020, 22(9): 93.
|
| [22] |
Sulman EP, Ismaila N, Armstrong TS, et al. Radiation therapy for glioblastoma: American society of clinical oncology clinical practice guideline endorsement of the American society for radiation oncology guideline[J]. J Clin Oncol, 2017, 35(3): 361-369.
|
| [23] |
Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma[J]. N Engl J Med, 2017, 376(11): 1027-1037.
|
| [24] |
Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial[J]. Lancet Oncol, 2012, 13(7): 707-715.
|
| [25] |
Ohno M, Miyakita Y, Takahashi M, et al. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged≥75 years[J]. Radiat Oncol, 2019, 14(1): 200.
|
| [26] |
Rusthoven CG, Koshy M, Sher DJ, et al. Combined-modality therapy with radiation and chemotherapy for elderly patients with glioblastoma in the temozolomide era: a national cancer database analysis[J]. JAMA Neurol, 2016, 73(7): 821-828.
|
| [27] |
Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, et al. Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review[J]. Cancers (Basel), 2019, 11(2): 174.
|
| [28] |
Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial[J]. JAMA, 2017, 318(23): 2306-2316.
|
| [29] |
Chokshi CR, Brakel BA, Tatari N, et al. Advances in immunotherapy for adult glioblastoma[J]. Cancers (Basel), 2021, 13(14): 3400.
|